Annual FCF
-$86.94 M
-$51.08 M-142.40%
December 31, 2023
Summary
- As of February 7, 2025, ABUS annual free cash flow is -$86.94 million, with the most recent change of -$51.08 million (-142.40%) on December 31, 2023.
- During the last 3 years, ABUS annual FCF has fallen by -$35.27 million (-68.27%).
- ABUS annual FCF is now -364.32% below its all-time high of $32.89 million, reached on December 31, 2012.
Performance
ABUS Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$20.74 M
-$6.23 M-42.96%
September 30, 2024
Summary
- As of February 7, 2025, ABUS quarterly free cash flow is -$20.74 million, with the most recent change of -$6.23 million (-42.96%) on September 30, 2024.
- Over the past year, ABUS quarterly FCF has dropped by -$1.35 million (-6.94%).
- ABUS quarterly FCF is now -151.38% below its all-time high of $40.36 million, reached on December 31, 2012.
Performance
ABUS Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$71.92 M
+$1.08 M+1.48%
September 30, 2024
Summary
- As of February 7, 2025, ABUS TTM free cash flow is -$71.92 million, with the most recent change of +$1.08 million (+1.48%) on September 30, 2024.
- Over the past year, ABUS TTM FCF has increased by +$6.99 million (+8.86%).
- ABUS TTM FCF is now -310.83% below its all-time high of $34.11 million, reached on March 31, 2013.
Performance
ABUS TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ABUS Free Cash Flow Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -142.4% | -6.9% | +8.9% |
3 y3 years | -68.3% | -21.1% | -100.5% |
5 y5 years | -26.0% | -21.1% | -100.5% |
ABUS Free Cash Flow Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -142.4% | at low | -200.9% | +24.4% | -141.2% | +17.3% |
5 y | 5-year | -142.4% | at low | -200.9% | +24.4% | -141.2% | +17.3% |
alltime | all time | -364.3% | at low | -151.4% | +24.4% | -310.8% | +17.3% |
Arbutus Biopharma Free Cash Flow History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$20.74 M(+43.0%) | -$71.92 M(-1.5%) |
Jun 2024 | - | -$14.51 M(-25.2%) | -$73.00 M(-7.5%) |
Mar 2024 | - | -$19.39 M(+12.1%) | -$78.92 M(-9.2%) |
Dec 2023 | -$86.94 M(+142.4%) | -$17.29 M(-20.7%) | -$86.94 M(+0.2%) |
Sep 2023 | - | -$21.82 M(+6.8%) | -$86.78 M(+3.6%) |
Jun 2023 | - | -$20.42 M(-25.5%) | -$83.74 M(-0.1%) |
Mar 2023 | - | -$27.42 M(+60.1%) | -$83.83 M(+133.7%) |
Dec 2022 | -$35.87 M(-47.5%) | -$17.12 M(-8.8%) | -$35.87 M(-6.6%) |
Sep 2022 | - | -$18.78 M(-8.4%) | -$38.41 M(+7.6%) |
Jun 2022 | - | -$20.50 M(-199.8%) | -$35.68 M(+19.7%) |
Mar 2022 | - | $20.54 M(-204.5%) | -$29.82 M(-56.4%) |
Dec 2021 | -$68.34 M(+32.3%) | -$19.66 M(+22.5%) | -$68.34 M(+7.0%) |
Sep 2021 | - | -$16.06 M(+9.7%) | -$63.84 M(+6.5%) |
Jun 2021 | - | -$14.64 M(-18.6%) | -$59.97 M(+10.7%) |
Mar 2021 | - | -$17.98 M(+18.6%) | -$54.20 M(+4.9%) |
Dec 2020 | -$51.67 M(-27.8%) | -$15.16 M(+24.5%) | -$51.67 M(+3.5%) |
Sep 2020 | - | -$12.19 M(+37.4%) | -$49.92 M(-18.8%) |
Jun 2020 | - | -$8.87 M(-42.6%) | -$61.46 M(-12.7%) |
Mar 2020 | - | -$15.45 M(+15.2%) | -$70.44 M(-1.6%) |
Dec 2019 | -$71.59 M(+3.8%) | -$13.41 M(-43.5%) | -$71.59 M(-5.2%) |
Sep 2019 | - | -$23.73 M(+33.0%) | -$75.48 M(+15.8%) |
Jun 2019 | - | -$17.84 M(+7.4%) | -$65.20 M(-0.3%) |
Mar 2019 | - | -$16.61 M(-4.0%) | -$65.40 M(-5.2%) |
Dec 2018 | -$69.00 M(+23.4%) | -$17.30 M(+28.7%) | -$69.00 M(+10.9%) |
Sep 2018 | - | -$13.44 M(-25.5%) | -$62.23 M(-4.3%) |
Jun 2018 | - | -$18.05 M(-10.7%) | -$65.01 M(+17.9%) |
Mar 2018 | - | -$20.21 M(+92.0%) | -$55.16 M(-1.3%) |
Dec 2017 | -$55.90 M(-9.7%) | -$10.53 M(-35.1%) | -$55.90 M(-11.0%) |
Sep 2017 | - | -$16.22 M(+97.8%) | -$62.80 M(+2.2%) |
Jun 2017 | - | -$8.20 M(-60.9%) | -$61.46 M(-13.5%) |
Mar 2017 | - | -$20.96 M(+20.3%) | -$71.02 M(+14.8%) |
Dec 2016 | -$61.88 M(+5.5%) | -$17.42 M(+17.1%) | -$61.88 M(-3.1%) |
Sep 2016 | - | -$14.88 M(-16.2%) | -$63.85 M(+22.6%) |
Jun 2016 | - | -$17.76 M(+50.2%) | -$52.09 M(-0.8%) |
Mar 2016 | - | -$11.82 M(-39.0%) | -$52.51 M(-10.5%) |
Dec 2015 | -$58.67 M | -$19.39 M(+522.2%) | -$58.67 M(+26.3%) |
Sep 2015 | - | -$3.12 M(-82.9%) | -$46.45 M(-7.5%) |
Jun 2015 | - | -$18.18 M(+1.1%) | -$50.21 M(+24.6%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2015 | - | -$17.98 M(+150.9%) | -$40.28 M(+198.9%) |
Dec 2014 | -$13.48 M(+80.6%) | -$7.17 M(+4.3%) | -$13.48 M(+242.5%) |
Sep 2014 | - | -$6.87 M(-16.8%) | -$3.94 M(+361.3%) |
Jun 2014 | - | -$8.26 M(-193.6%) | -$853.00 K(-119.4%) |
Mar 2014 | - | $8.82 M(+271.7%) | $4.40 M(-159.0%) |
Dec 2013 | -$7.46 M(-122.7%) | $2.37 M(-162.6%) | -$7.46 M(-124.4%) |
Sep 2013 | - | -$3.79 M(+26.2%) | $30.52 M(-6.9%) |
Jun 2013 | - | -$3.00 M(-1.2%) | $32.80 M(-3.9%) |
Mar 2013 | - | -$3.04 M(-107.5%) | $34.11 M(+3.7%) |
Dec 2012 | $32.89 M(-516.8%) | $40.36 M(-2765.7%) | $32.89 M(-515.6%) |
Sep 2012 | - | -$1.51 M(-10.2%) | -$7.91 M(+22.6%) |
Jun 2012 | - | -$1.69 M(-60.5%) | -$6.46 M(-27.9%) |
Mar 2012 | - | -$4.26 M(+842.6%) | -$8.95 M(+13.4%) |
Dec 2011 | -$7.89 M(-34.7%) | -$452.20 K(+706.1%) | -$7.89 M(-29.9%) |
Sep 2011 | - | -$56.10 K(-98.7%) | -$11.25 M(-17.1%) |
Jun 2011 | - | -$4.18 M(+30.4%) | -$13.58 M(+42.6%) |
Mar 2011 | - | -$3.20 M(-16.0%) | -$9.52 M(-21.2%) |
Dec 2010 | -$12.08 M(+74.8%) | -$3.81 M(+60.2%) | -$12.08 M(+13.4%) |
Sep 2010 | - | -$2.38 M(+1864.8%) | -$10.65 M(+12.2%) |
Jun 2010 | - | -$121.20 K(-97.9%) | -$9.50 M(-14.8%) |
Mar 2010 | - | -$5.76 M(+141.0%) | -$11.15 M(+61.4%) |
Dec 2009 | -$6.91 M(-26.9%) | -$2.39 M(+94.9%) | -$6.91 M(+7.7%) |
Sep 2009 | - | -$1.23 M(-30.8%) | -$6.41 M(-27.1%) |
Jun 2009 | - | -$1.77 M(+16.5%) | -$8.80 M(-13.2%) |
Mar 2009 | - | -$1.52 M(-19.8%) | -$10.15 M(+7.4%) |
Dec 2008 | -$9.45 M(+102.0%) | -$1.90 M(-47.6%) | -$9.45 M(+25.1%) |
Sep 2008 | - | -$3.62 M(+16.1%) | -$7.55 M(+91.8%) |
Jun 2008 | - | -$3.11 M(+277.5%) | -$3.94 M(+377.5%) |
Mar 2008 | - | -$824.90 K | -$824.90 K |
Dec 2007 | -$4.68 M(+75.1%) | - | - |
Dec 2006 | -$2.67 M(-81.7%) | - | - |
Dec 2005 | -$14.62 M(-14.7%) | - | - |
Dec 2004 | -$17.13 M(-38.3%) | - | - |
Dec 2003 | -$27.75 M(+38.0%) | - | - |
Dec 2002 | -$20.11 M(+83.7%) | - | - |
Dec 2001 | -$10.95 M(+27.9%) | - | - |
Dec 2000 | -$8.56 M(+17.3%) | - | - |
Dec 1999 | -$7.29 M(-33.3%) | - | - |
Dec 1998 | -$10.93 M | - | - |
FAQ
- What is Arbutus Biopharma annual free cash flow?
- What is the all time high annual FCF for Arbutus Biopharma?
- What is Arbutus Biopharma annual FCF year-on-year change?
- What is Arbutus Biopharma quarterly free cash flow?
- What is the all time high quarterly FCF for Arbutus Biopharma?
- What is Arbutus Biopharma quarterly FCF year-on-year change?
- What is Arbutus Biopharma TTM free cash flow?
- What is the all time high TTM FCF for Arbutus Biopharma?
- What is Arbutus Biopharma TTM FCF year-on-year change?
What is Arbutus Biopharma annual free cash flow?
The current annual FCF of ABUS is -$86.94 M
What is the all time high annual FCF for Arbutus Biopharma?
Arbutus Biopharma all-time high annual free cash flow is $32.89 M
What is Arbutus Biopharma annual FCF year-on-year change?
Over the past year, ABUS annual free cash flow has changed by -$51.08 M (-142.40%)
What is Arbutus Biopharma quarterly free cash flow?
The current quarterly FCF of ABUS is -$20.74 M
What is the all time high quarterly FCF for Arbutus Biopharma?
Arbutus Biopharma all-time high quarterly free cash flow is $40.36 M
What is Arbutus Biopharma quarterly FCF year-on-year change?
Over the past year, ABUS quarterly free cash flow has changed by -$1.35 M (-6.94%)
What is Arbutus Biopharma TTM free cash flow?
The current TTM FCF of ABUS is -$71.92 M
What is the all time high TTM FCF for Arbutus Biopharma?
Arbutus Biopharma all-time high TTM free cash flow is $34.11 M
What is Arbutus Biopharma TTM FCF year-on-year change?
Over the past year, ABUS TTM free cash flow has changed by +$6.99 M (+8.86%)